Telesis Bio Statistics
Total Valuation
Telesis Bio has a market cap or net worth of 785,809. The enterprise value is 43.66 million.
Market Cap | 785,809 |
Enterprise Value | 43.66M |
Important Dates
The next estimated earnings date is Thursday, March 20, 2025.
Earnings Date | Mar 20, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Telesis Bio has 1.78 million shares outstanding. The number of shares has increased by 3.53% in one year.
Current Share Class | n/a |
Shares Outstanding | 1.78M |
Shares Change (YoY) | +3.53% |
Shares Change (QoQ) | +2.45% |
Owned by Insiders (%) | 20.14% |
Owned by Institutions (%) | 4.88% |
Float | 742,452 |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.04 |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -0.91 |
EV / Sales | 2.56 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -1.83 |
Financial Position
The company has a current ratio of 1.23, with a Debt / Equity ratio of 4.21.
Current Ratio | 1.23 |
Quick Ratio | 0.87 |
Debt / Equity | 4.21 |
Debt / EBITDA | n/a |
Debt / FCF | -0.68 |
Interest Coverage | -26.84 |
Financial Efficiency
Return on equity (ROE) is -178.99% and return on invested capital (ROIC) is -33.51%.
Return on Equity (ROE) | -178.99% |
Return on Assets (ROA) | -30.10% |
Return on Capital (ROIC) | -33.51% |
Revenue Per Employee | 436,769 |
Profits Per Employee | -1.23M |
Employee Count | 147 |
Asset Turnover | 0.26 |
Inventory Turnover | 3.37 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -93.69% in the last 52 weeks. The beta is 1.76, so Telesis Bio's price volatility has been higher than the market average.
Beta (5Y) | 1.76 |
52-Week Price Change | -93.69% |
50-Day Moving Average | 1.05 |
200-Day Moving Average | 3.71 |
Relative Strength Index (RSI) | 37.23 |
Average Volume (20 Days) | 6,761 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | 0.12 |
Income Statement
In the last 12 months, Telesis Bio had revenue of 17.03 million and -47.93 million in losses. Loss per share was -28.02.
Revenue | 17.03M |
Gross Profit | 7.98M |
Operating Income | -31.25M |
Pretax Income | -45.07M |
Net Income | -47.93M |
EBITDA | -28.69M |
EBIT | -31.25M |
Loss Per Share | -28.02 |
Balance Sheet
The company has 4.51 million in cash and 16.29 million in debt, giving a net cash position of -11.78 million or -6.63 per share.
Cash & Cash Equivalents | 4.51M |
Total Debt | 16.29M |
Net Cash | -11.78M |
Net Cash Per Share | -6.63 |
Equity (Book Value) | 3.87M |
Book Value Per Share | -15.35 |
Working Capital | 1.49M |
Cash Flow
In the last 12 months, operating cash flow was -22.87 million and capital expenditures -992,000, giving a free cash flow of -23.86 million.
Operating Cash Flow | -22.87M |
Capital Expenditures | -992,000 |
Free Cash Flow | -23.86M |
FCF Per Share | -13.44 |
Margins
Gross margin is 46.87%, with operating and profit margins of -183.44% and -267.41%.
Gross Margin | 46.87% |
Operating Margin | -183.44% |
Pretax Margin | -264.56% |
Profit Margin | -267.41% |
EBITDA Margin | -168.42% |
EBIT Margin | -183.44% |
FCF Margin | n/a |
Dividends & Yields
Telesis Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -3.53% |
Shareholder Yield | -3.53% |
Earnings Yield | -6,332.16% |
FCF Yield | -3,036.62% |
Stock Splits
The last stock split was on May 9, 2024. It was a reverse split with a ratio of 0.0555556.
Last Split Date | May 9, 2024 |
Split Type | Reverse |
Split Ratio | 0.0555556 |
Scores
Telesis Bio has an Altman Z-Score of -13.79. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -13.79 |
Piotroski F-Score | n/a |